A time-cost augmented economic evaluation of oral deferasirox versus infusional dereroxmine for patients with iron overload in South Korea

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Kim, Jinhyun ^a   Kim, Younhee ^a  

^a Seoul National University   (South Korea)

Author keywords

Compliance; Cost effectiveness analysis; Cost utility analysis; Iron chelating agents

Indexed keywords

DEFERASIROX; DEFEROXAMINE; IRON;

ADULT; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INFUSION; ECONOMIC EVALUATION; HUMAN; INJECTION; IRON OVERLOAD; MONEY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SOUTH KOREA; TIME COST AUGMENTED ANALYSIS;

EID: 72149097314     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00633.x     Document Type: Article

References (19)

1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997 89 : 739 761.
2. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996 95 : 26 36.
3. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007 138 : 407 421.
4. Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with [beta]-thalassemia. Clin Ther 2007 29 : 909 917.
5. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006 107 : 3455 3462.
6. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006 91 : 873 880.
7. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008 80 : 168 176.
8. Stumpf JL. Deferasirox. Am J Health Syst Pharm 2007 64 : 606 616.
9. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007 136 : 501 508.
10. Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (exjade? ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Acta Haematol 2008 119 : 133 141.
11. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007 47 : 1919 1929.
12. Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000 355 : 2051 2052.
13. Delea TE, Sofrygin O, Thomas SK, et al. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US health care system perspective. Pharmacoeconomics 2007 25 : 329 342.
14. Fischer R, Longo F, Nielsen P, et al. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003 121 : 938 948.
15. Abetz L, Baladi JF, Jones P, et al. The impact of iron overload and its treatment on quality of life: results from a literature review. Health Qual Life Outcomes 2006 4 : 73 8.
16. Osborne RH, De Abreu Lourenco R, Dalton A, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health 2007 10 : 451 456.
17. Karnon J, Tolley K, Oyee J, et al. Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Curr Med Res Opin 2008 24 : 1609 1621.
18. Kim J, Kim Y. Economic evaluation of iron agents: oral deferasirox versus infusional deferoxamine. Korean J. hematol 2008 43 : 89 97
19. Korean T.E. Thomas S.K. Baladi J.-F. et al. Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (exjade(R), ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic syndrome. ASH Annu Meet Abstr 2005 106 5585.